Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.66 |
| ▸ | BRD2 | P25440 | 2/20 | 0.66 |
| ▸ | MLYCD | O95822 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.51 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300240 | 0.83 | BRD4 (0.70) | BRD4BRD2MLYCDJAK2BRD3 | |
| SCHEMBL14196935 | 0.81 | BRD4 (0.61) | BRD4BRD2MLYCDBRD3CREBBP | |
| SCHEMBL16404607 | 0.80 | BRD4 (0.66) | BRD4BRD2MLYCD | |
| SCHEMBL14678367 | 0.80 | BRD4 (0.66) | BRD4BRD2MLYCDBRD3CREBBP | |
| SCHEMBL1772573 | 0.80 | BRD4 (0.66) | BRD4BRD2MLYCDJAK2BRD3 | |
| SCHEMBL12362813 | 0.80 | BRD4 (0.66) | BRD4BRD2MLYCDCREBBPERN1 | |
| SCHEMBL25975868 | 0.79 | BRD4 (0.59) | BRD4BRD2MLYCDJAK2BRD3 | |
| SCHEMBL20093786 | 0.79 | JAK2 (0.57) | BRD4BRD2JAK2BRD3CREBBP | |
| 3,5-Dimethyl-4-Phenylisoxazole SCHEMBL12134072 | 0.79 | BRD4 (1.00) | BRD4BRD2MLYCDTDO2CREBBP | |
| Hydrochloric Acid SCHEMBL23174957 | 0.78 | BRD4 (0.63) | BRD4BRD2MLYCDCREBBPERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116568676-A | IL-17A modulators | 赛诺菲 | 2023-08-08 | — | — | CN | disclosed |
| CN-116547275-A | IL-17A modulators | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| EP-4157827-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157828-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
| WO-2020127685-A1 | AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020081682-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2017144393-A1 | 2-SUBSTITUTED 5-(PHENYL)-1,2-DIHYDRO-3H-3-BENZAZEPINE-3-CARBOXAMIDE DERIVATIVES AS BRD4 INHIBITORS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-31 | — | — | WO | disclosed |
| US-8486962-B2 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2013-07-16 | — | — | US | disclosed |
| EP-1888063-B1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | NAT1, CYP1A2, CYP51A1 | BRD4 2165/4885BRD2 1864/4885MLYCD 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.